Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets

European Neuropsychopharmacology

Volumn 15, Issue 1, 2005, Pages 111-117

  Chue, Pierre ^a,e   Eerdekens, Marielle ^b   Augustyns, Ilse ^b   Lachaux, Bernard ^c   Molčan, Peter ^d   Eriksson, Lars ^e   Pretorius, H ^f   David, Anthony S ^g  

^a UNIVERSITY OF ALBERTA   (Canada)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c Centre Hospitalier Paul Guiraud   (France)

^d Psychiatricka Klinika   (Slovakia)

^e Sweden ^*  (Canada)

^f UNIVERSITY OF PRETORIA   (South Africa)

^g KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Depot formulation; Double blind trial; Long acting injectable risperidone; Oral risperidone; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; PROLACTIN; RISPERIDONE;

ADULT; AGED; ANXIETY DISORDER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG WITHDRAWAL; DYSMENORRHEA; EDEMA; HEADACHE; HUMAN; INJECTION PAIN; INSOMNIA; LACTATION DISORDER; MAJOR CLINICAL STUDY; MOTOR DYSFUNCTION; MULTICENTER STUDY; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; SIDE EFFECT; TARDIVE DYSKINESIA; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; RISPERIDONE; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 9644257391     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2004.07.003     Document Type: Article

References (23)

1. C.E. Adams, M.K.P. Fenton, S. Quraishi, and A.S. David Systemic meta-review of depot antipsychotic drugs for people with schizophrenia Br. J. Psychiatry 179 2001 290 299
2. D.B. Allison, J.L. Mentore, M. Heo, L.P. Chandler, J.C. Cappelleri, M.C. Infante, and P.J. Weiden Antipsychotic-induced weight gain: a comprehensive research synthesis Am. J. Psychiatry 156 1999 1686 1696
3. American Psychiatric Association Practice guideline for the treatment of patients with schizophrenia Am. J. Psychiatry 154 Suppl 4 1997 1 63
4. J.J.S. Bains, and O.B. Neilssen Combining depot antipsychotic medications with novel antipsychotics in forensic patients: a practice in search of a principle Psychiatri. Bull. 27 2003 14 16
5. G. Chouinard, A. Ross-Chouinard, L. Annable, and B.D. Jones Extrapyramidal symptom rating scale (Abstract) Can. J. Neurol. Sci. 7 1980 233
6. J.M. Davis, and N. Chen Clinical profile of an atypical antipsychotic: risperidone Schizophr. Bull. 28 2002 43 61
7. J.M. Davis, L. Matalon, M.D. Watanabe, and L. Blake Depot antipsychotic drugs: place in therapy Drugs 47 1994 741 743
8. R.J. Diamond Enhancing medication use in schizophrenic patients J. Clin. Psychiatry 44 1983 7 14
9. R.L. Findling, M.G. Aman, M. Eerdekens, A. Derivan, B. Lyons Risperidone Disruptive Behaviors Group Long-term, open-label study of risperidone in children with severe disruptive behaviors and below-average IQ Am. J. Psychiatry 161 2004 667 684
10. W.W. Fleischhacker, M. Eerdekens, K. Karcher, G. Remington, P.M. Llorca, W. Chrzanowski, S. Martin, and O. Gefvert Treatment of schizophrenia with long-acting risperidone: a 12-month evaluation of the first long-acting second-generation antipsychotic J. Clin. Psychiatry 64 2003 1250 1257
11. W.M. Glazer, and J.M. Kane Depot neuroleptic therapy: an underutilized treatment option J. Clin. Psychiatry 53 1992 426 433
12. W. Guy ECDEU Assessment Manual for Psychopharmacology, Revised 1976 National Institute of Mental Health Rockville, Maryland
13. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) Consolidated guideline on good clinical practice in the conduct of clinical trials on medicinal products for human use Int. Dig. Health Legis. 48 1997 231 234
14. J.M. Kane Pharmacologic treatment of schizophrenia Biol. Psychiatry 46 1999 1396 1408
15. J.M. Kane, E. Aguglia, A.C. Altamura, J.L.A. Gutierrez, N. Brunello, W.W. Fleischhacker, W. Gaebel, J. Gerlach, J.-D. Guelfi, W. Kissling, Y.D. Lapierre, E. Lindstrom, J. Mendlewicz, G. Racagni, L.S. Carulla, and N. Schooler Guidelines for depot antipsychotic treatment in schizophrenia European Neuropsychopharmacology Consensus Conference in Sienna, Italy Eur. Neuropsychopharmacol. vol. 8 1998 55 66
16. J.M. Kane, M. Eerdekens, J.P. Lindenmayer, S.J. Keith, M. Lesem, and K. Karcher Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic Am. J. Psychiatry 160 2003 1125 1132
17. S.R. Kay, A. Fiszbein, and L.A. Opler The Positive and Negative Syndrome Scale (PANSS) for schizophrenia Schizophr. Bull. 13 1987 261 276
18. D.L. Kleinberg, J.M. Davis, R. de Coster, B. Van Baelen, and M. Brecher Prolactin levels and adverse events in patients treated with risperidone J. Clin. Psychopharmacol. 19 1999 57 61
19. S.R. Marder, J.M. Davis, and G. Chouinard The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials J. Clin. Psychiatry 58 1997 538 546
20. Y. Sarfati, V. Olivier, and M. Bouhassira Utilisation des nouveaux antipsychotiques dans le traitement de la schizophrenie. Une enquete europeenne New antipsychotics in the treatment of schizophrenia. A European survey Encephale 25 1999 658 666
21. N.R. Schooler, and J.M. Kane Research diagnosis for tardive dyskinesia Arch. Gen. Psychiatry 39 1982 486 487 (in French)
22. J. Walburn, R. Gray, K. Gournay, S. Quraishi, and A.S. David Systematic review of patient and nurse attitudes to depot antipsychotic medication Br. J. Psychiatry 179 2001 300 307
23. P.J. Weiden, R. Aquila, L. Dalheim, and J.M. Standard Switching antipsychotic medications J. Clin. Psychiatry 58 Suppl 10 1997 63 72